Drug profile · INN
carmustine
GLIADEL
carmustine (GLIADEL) is a glutathione reductase inhibitor. Associated with Eisai Co.,. Route of administration: intracranial. Current US regulatory status: approved.
Drug details — carmustine
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INTRACRANIAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
carmustine (GLIADEL) is a glutathione reductase inhibitor. Associated with Eisai Co.,. Route of administration: intracranial. Current US regulatory status: approved.
Key facts
Mechanism of action
Glutathione reductase inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is carmustine?
carmustine (GLIADEL) is a glutathione reductase inhibitor. Associated with Eisai Co.,. Route of administration: intracranial. Current US regulatory status: approved.
What is the brand name for carmustine?
GLIADEL is a marketed brand name for carmustine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of carmustine?
carmustine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.